Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.

Article Details

Citation

Copy to clipboard

Gele T, Gouget H, Furlan V, Becker PH, Taburet AM, Lambotte O, Barrail-Tran A

Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.

Antimicrob Agents Chemother. 2020 Oct 20;64(11). pii: AAC.00895-20. doi: 10.1128/AAC.00895-20. Print 2020 Oct 20.

PubMed ID

32868324 [ View in PubMed

]

Abstract

This study aimed to characterize in vitro dolutegravir (DTG) and bictegravir (BIC) binding. They had a preferential binding to human serum albumin (HSA) with two classes of albumin sites. Human alpha-1-acid glycoprotein (HAAG) binding of DTG and BIC showed an atypical nonlinear binding. The low-affinity site on HSA, the main plasma binding protein, suggests that the high protein binding rate should not impair passive diffusion.

DrugBank Data that Cites this Article

Drug Carriers

Drug	Carrier	Kind	Organism	Pharmacological Action	Actions
Dolutegravir	alpha1-acid glycoprotein (Protein Group)	Protein group	Humans	No	Binder	Details
Dolutegravir	Serum albumin	Protein	Humans	No	Binder	Details